You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Arvinas ended the third quarter with $558.9 million in cash and securities and expects cash into the second half of 2028. Milestones include ARV 393 data in December and ARV 102 Phase 1B initiation in 2027.
Arvinas, Inc. registered up to $400,000,000 of securities for future sales, including up to $200,000,000 of common stock under an amended and restated equity distribution agreement with Piper Sandler & Co. and Cantor Fitzgerald & Co.
Arvinas and Pfizer licensed VEPPANU to Rigel following its FDA approval for ESR1-mutated advanced or metastatic breast cancer; the agreement included a $70.0 million upfront payment.
Arvinas initiated dosing in ARV-6723’s Phase 1/2 trial and reported $558.9 million in cash, cash equivalents, restricted cash and marketable securities, sufficient to fund operations into the second half of 2028.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
TL;DR. Arvinas advanced ARV-393, ARV-6723 and ARV-027, reported early ARV-393 responses and ARV-102 biomarker movement, and expects its cash to fund operations into the second half of 2028. Risks include sharply lower revenue, a wider net loss, a lower cash balance, ARV-102's U.S. clinical hold, ARV-806's dependence on a partner, and limitations in the initial ARV-393 durability and ARV-102 clinical-benefit data.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| ARV-027 | $3.3M | the three months ended June 30, 2026 filing | — |
| ARV-102 | $5.1M | the three months ended June 30, 2026 filing | — |
| ARV-393 | $4.8M | the three months ended June 30, 2026 filing | — |
| ARV-806 | $5.6M | the three months ended June 30, 2026 filing | — |
| Bavdegalutamide (ARV-110) | -$0.4M | the three months ended June 30, 2026 filing | — |
| Cash used in operations (net of Rigel License Agreement receipts) | $114.3M | six months ended June 30, 2026 | — |
| Cash, cash equivalents, and marketable securities | $567.9M | As of June 30, 2026 | — |
| Non-GAAP general and administrative expenses non-GAAP | 31.3M | the six months ended June 30, 2026 | — |
| Non-GAAP research and development expenses non-GAAP | 105.7M | the six months ended June 30, 2026 | — |
| Non-program-specific external expense | $8.5M | the three months ended June 30, 2026 filing | — |
| Other programs | $1.3M | the three months ended June 30, 2026 filing | — |
| Total program-specific external expense | $24.2M | the three months ended June 30, 2026 filing | — |
| Vepdegestrant (ARV-471) | $4.5M | the three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ARVN
this stock
Arvinas, Inc.
|
$446.61M | -42.5% | -0.3% | — | 8.8% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.56B | +18.8% | +46.2% | 34.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$98.84B | +23.8% | +20.8% | 21.1 | 2.1% |
|
MRNA
Moderna, Inc.
|
$90.38B | +657.4% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$66.05B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Arvinas, Inc. registered up to $400,000,000 of securities for future sales, including up to $200,000,000 of common stock under an amended and restated equity distribution agreement with Piper Sandler & Co. and Cantor Fitzgerald & Co.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ARVN | +6.4% | -2.2% | -23.5% | -13.2% | -42.5% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | +3.8% | -1.0% | -24.0% | -13.1% | -53.1% |
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
